First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

Phase 2 study of obinutuzumab (GA-101), ibrutinib and venetoclax (CLL2-GIVe) in patients with untreated high-risk chronic lymphocytic leukemia

(2022) Henriette Huber et al.   BLOOD

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase 3 iLLUMINATE trial

(2022) Carol Moreno et al.   HAEMATOLOGICA

Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

(2022) Jeff P. Sharman et al.   LEUKEMIA

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

(2022) John F. Seymour et al.   BLOOD

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

(2022) Constantine S. Tam et al.   BLOOD

Long-term Outcomes for Ibrutinib-Rituximab and Chemoimmunotherapy in CLL: Updated Results of the E1912 Trial

(2022) Tait D. Shanafelt et al.   BLOOD

Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial

(2022) Arnon P Kater et al.   LANCET ONCOLOGY

Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial

(2022) Sabina Kersting et al.   Lancet Haematology

Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study

(2022) John N. Allan et al.   BLOOD

Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study

(2021) Matthew S Davids et al.   LANCET ONCOLOGY

Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial

(2021) Peter Hillmen et al.   BLOOD

Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study

(2021) Othman Al-Sawaf et al.   JOURNAL OF CLINICAL ONCOLOGY

Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial

(2021) Jacob D Soumerai et al.   Lancet Haematology

COVID-19 among fit patients with CLL treated with venetoclax-based combinations

(2020) Moritz Fürstenau et al.   LEUKEMIA

Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia

(2020) Kerry A. Rogers et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia

(2019) Ian W. Flinn et al.   BLOOD

Ibrutinib and Venetoclax for First-Line Treatment of CLL

(2019) Nitin Jain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study

(2019) Peter Hillmen et al.   JOURNAL OF CLINICAL ONCOLOGY

Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

(2019) Tait D. Shanafelt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

(2019) Kirsten Fischer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

(2018) John F. Seymour et al.   NEW ENGLAND JOURNAL OF MEDICINE

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study

(2015) A C Rawstron et al.   LEUKEMIA

Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial

(2012) Sebastian Böttcher et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD

A Manual of Guidelines to Score the Modified Cumulative Illness Rating Scale and Its Validation in Acute Hospitalized Elderly Patients

(2008) Fabio Salvi et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY